Piper Sandler analyst Biren Amin raised the firm’s price target on Aclaris Therapeutics (ACRS) to $11 from $7 and keeps an Overweight rating on the shares following the company’s update ATI-052 & ATI-2138 last week. For ATI-052, the firm compared TARC data in Phase 1 healthy volunteers; TARC has the greatest evidence-based support of any AD biomarker for correlating with disease severity/therapeutic response. Comparing ATI-052’s Phase 1 data to other Ab programs shows ATI-052 has a greater ability to decrease TARC vs Dupixent, Bambusa’s BBT001, and Apogee’s zumilokibart. ATI-052’s safety profile is also devoid of ADAs which has readthrough to efficacy on longer-term dosing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics initiated with a Buy at Guggenheim
- Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
- Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
- Aclaris Reports Positive ATI-052 Phase 1a Trial Results
- Aclaris Therapeutics management to meet virtually with Craig-Hallum